Funded Biomarker Testing
5 items
Immunohistochemical evaluation, where indicated, to assess line of differentiation for classification
Funded Biomarker Disease Site: Soft Tissue
Biomarker:
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, The Ottawa Hospital
Molecular interrogation, where indicated, for classification, prognostic and/or therapeutic purposes.
Funded Biomarker Disease Site: Soft Tissue
Biomarker: Refer to 2023 Consensus Pathology Recommendations for Mesenchymal Tumours of Soft Tissue and Bone
Testing Method:Sequencing
Testing Site: Mount Sinai Hospital, The Ottawa Hospital
Reflex testing on newly diagnosed CD117 (cKIT) positive Gastrointestinal Stromal Tumours
Funded Biomarker Disease Site: Soft Tissue
Biomarker: BRAF, KIT, PDGFRA (Optional 23/24 - SDH, NTRK (fusion))
Testing Method:Sequencing
Testing Site: Hamilton Health Sciences, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, University Health Network
Reflex testing on newly diagnosed CD117 (cKIT) positive Gastrointestinal Stromal Tumours
Funded Biomarker Disease Site: Soft Tissue
Biomarker: SDHB
Testing Method:Immunohistochemistry (IHC)
Testing Site: London Health Sciences Centre, Mount Sinai Hospital
Review of tumour by a subspecialist Pathologist for classification
Funded Biomarker Disease Site: Soft Tissue
Biomarker:
Testing Method:
Testing Site: Hamilton Health Sciences, Mount Sinai Hospital, The Ottawa Hospital